Keywords: Exelixis, Sanofi, PI3K, Cancer collaboration

Exelixis and Sanofi terminate $1 billion cancer deal

Article | 23 December 2011

Print This

US biotechnology firm Exelixis (Nasdaq: EXEL) says its oncology deal with French drug Major Sanofi (Euronext: SAN), for the discovery ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in